Krystal Biotech 3Q 2026 Conference Call - KRYSTAL BIOTECH INC

Explicit Guidance:

• Full-Year 2026 Expenses: Revised non-GAAP R&D and SG&A guidance to $155–$165 million, down from the prior range of $175–$195 million, driven by insurance proceeds and reduced legal/marketing costs.
• Capital Allocation: Board authorized a share repurchase program of up to $400 million, to be deployed over the next two years (2026–2027).
• Cash Position: Projected to maintain $1.2+ billion in cash and investments to support global expansion and capital returns.

Business-Segment Outlook:

• VizuVec (International):
  • Italy: Pricing concluded; expects launch in early 2027.
  • Spain: Pricing discussions ongoing with a decision expected by end of 2026; patients already accessing via exceptional regional funding for a potential 2027 launch.
  • France: Pricing negotiations active within a standard 13-month framework (currently ~6 months in); no specific launch date provided but expected within this timeline.
  • Japan: Prescription restrictions expected to lift in November–December 2026, shifting dosing frequency from twice-monthly to once-monthly, which is anticipated to accelerate adoption.
• VizuVec (U.S.):
  • Reimbursement: Over 760 approvals secured; expanding physician base by adding 80+ new prescribers per quarter.
  • Administration: 80% of patients now self-administer at home; focus shifting to treatment retention and evolving wound-care needs.
  • Outlook: Expect sustained growth driven by greater treatment flexibility and the remaining population of undiagnosed/misdiagnosed patients.

Market and Competitive Outlook:

• VizuVec: Pricing in Germany and Italy recognized as "meaningful," providing a strong foundation for global revenue growth; expect accruals to stabilize in major markets as pricing agreements finalize.
• Gorlin Syndrome (KB113): Potential for an abscopal effect (systemic response in non-injected lesions) observed in pilot; expects a pivotal trial feasible with <100 patients due to high response rates, distinct from standard oncology study designs.
• Ocular DEB (KB803): Study enrollment targeted for completion by February 2027; top-line results expected shortly thereafter.
• NK (KB801): Enrollment progressing slower than anticipated due to stringent criteria (excluding spontaneous lesion resolution) and site activation delays; expects enrollment and top-line results by 2027.
• Cystic Fibrosis (KB407): Interim results expected in the first half of 2027; on track for a registrational study start in 2027.
• Haley-Haley (KB111): Enrollment of 5 patients completed; data update expected before year-end 2026 to inform next steps with the FDA.
• Oncology (KB707): Expect to enroll and dose 70 patients at the selected regimen by mid-2027; results to inform subsequent registration plans.

Macro / Industry Outlook:

• Regulatory: Active engagement with the FDA via the Complex Innovative Design Meeting Program for CF/AATD; seeking alignment on registrational pathways for multiple indications.
• Pricing/Reimbursement: Management views international pricing trends as favorable, with Germany and Italy having concluded negotiations, reducing revenue volatility. France and Spain are viewed as near-term catalysts.
• Clinical Infrastructure: Expanding trial networks to 22+ U.S. sites and activating additional sites in France, Spain, and the UK to overcome enrollment bottlenecks.

Strategic Initiatives:

• Pipeline Expansion: Aggressively advancing rare dermatology (Gorlin, Haley-Haley), ophthalmology (Ocular DEB), and pulmonary (CF, AATD) indications to build a diversified revenue base beyond VizuVec.
• Capacity/Access: Extending home administration pathways (e.g., France retrocession) to reduce treatment burden and expand the prescriber network.
• Shareholder Returns: Balancing capital allocation between pipeline investment and opportunistic buybacks to support intrinsic value growth.

Risks and Headwinds to Outlook:

• Clinical Enrollment Delays: Slower than expected enrollment in NK (KB801) due to narrow eligibility criteria, site contract delays (academic sites), and patient withdrawals due to travel/compliance issues in Ocular DEB (KB803).
• Regulatory/Timing Risks: Clinical readouts (Gorlin, Haley-Haley) may take longer than initially hoped; specific timing for France pricing is contingent on a standard 13-month negotiation process.
• Adoption Risks: Japan growth may initially be constrained by prescription restrictions; Ocular DEB and NK face competition from existing therapies (e.g., Oxovate) and placebo-controlled trial challenges.
• Financial Variability: Ex-U.S. revenue may remain volatile until pricing is finalized in all major territories (UK, Spain, France).

Management Tone on the Future:

• Confidence: High confidence in the commercial growth of VizuVec and the scientific potential of the pipeline ("encouraging," "robust," "well-positioned").
• Pivot: Acknowledges delays in clinical timelines but maintains optimism regarding eventual outcomes and FDA alignment.
• Capital Discipline: Expresses strong conviction in the company's financial health, citing the $1.2B cash position and $400M buyback authorization as evidence of a "strong foundation" and confidence in long-term prospects.

Miscellaneous:

• Tax Rate: Prior year benefits (Section 174 reversal, valuation allowance release) were non-recurring; no specific tax rate guidance provided for the future.
• Gross Margin: Current quarter gross margin at 94% (down from 96% prior year) due to early-stage international sales lacking U.S. manufacturing optimizations; expects margin expansion as international scale increases.